NOVELTY – Vaccine is attenuated by a pathogenic bacterial strain, where attenuation corresponds to gene silencing of a gene encoding integration host factor (IHF). The mutants are neutral for IHF himA and himD genes. USE – Vaccine used with vaccine vectors for carrying antigens and multifactorial vaccine strains for stimulating humoral or cellular immune response against infection by pathogenic bacterium Salmonella (all claimed). ADVANTAGE – The vaccine is safe due to its high attenuation and is able to induce ten types of immune responses in the vertebrate host. DETAILED DESCRIPTION – An INDEPENDENT CLAIM is also included for a method for constructing attenuated strain, which involves: (A) processing recombination of pathogenic bacteria with a bacteriophage that inhibits recC gene product (ExoV) system of the host and promotes the recombination of linear fragments in the DNA target; (B) processing allelic exchange of the gene encoding the IHF by recombination cassette comprising an enhancement gene by using an initiator; and (C) eliminating accessory genes present in the recombination cassette containing recombinase which is expressed by a plasmid gene.
B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); D16 (Fermentation industry – including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)